611 W. Union Street
Benson, AZ 85602
(520) 586-0800

Health Choice Integrated Care crisis Line
1-877-756-4090

NurseWise 24-Hour Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530



SEABHS
611 W. Union Street
Benson, AZ 85602
(520) 586-0800

NurseWise 24-Hr Crisis Line
1-866-495-6735

NAZCARE Warm Line
1-888-404-5530


powered by centersite dot net

Getting Started
Here are some forms to get started. These can be printed and brought with you so that you can pre-fill out some known info ahead of time. More...


Cancer
Resources
Basic InformationLatest News
Lack of Training Linked to Cancer Patient Caregiver BurdenMelanoma Isn't the Only Serious Skin CancerMany With Cancer Hospitalized, Undergo Imaging at End of Life$100 Sweetens the Pot for a ColonoscopyVascular Targeted Photodynamic Tx Aids Low-Risk Prostate CancerObesity in Teen Years Tied to Colon Cancer Risk in AdulthoodASCO Addresses Cancer Drug PricingSenator McCain Faces a Tough Cancer FoeMore Patients OK'd for Cancer Trials Under Obamacare: StudyInsured, But Still Barred From Top-Tier Cancer CentersMany Terminal Cancer Patients Remain in DenialSingle-Dose PCV13 Immunogenic, Safe in Pediatric OncologyDoctors' Group Offers Ideas for Easing Cancer Costs'Nipple-Sparing' Mastectomies Don't Raise Odds of Cancer's Return: StudyNerlynx Approved to Help Prevent Breast Cancer's ReturnLittle Evidence That Vasectomy Raises Prostate Cancer RiskWait-and-Scan Strategy Feasible for Head, Neck ParagangliomaHigher Nodal Yield Tied to Lower Mortality in Oral Cavity CancerChange to Cervical Screening Guidelines Impacted ChlamydiaBlood Test for Early Detection of Pancreatic Cancer Feasible'Observation' Best Option for Most Low-Risk Prostate CancerAre Big Men More Prone to Aggressive Prostate Cancer?Rivaroxaban OK for Stroke Prevention in Cancer PatientsNew Test May Help Spot Pancreatic Cancer EarlyDecisional Regret Doesn't Differ by Treatment in Prostate CancerEasier Colon Exam Boosts Screening, But Insurers May Not PayParkinson's Patients Deemed at Higher Risk of MelanomaMost Breast Cancer Patients Have Help Choosing TreatmentsFor Holocaust Survivors, Raised Risk of CancerParkinson's Disease and Melanoma May Occur Together, Study FindsGermline Mutations Up in Men With Prostate CA, One Other CACancer Deaths Higher in Rural America, CDC ReportsFDA Widens Access to 'Cooling Cap' to Stop Hair Loss in Cancer PatientsNivolumab Rx Beyond Progression Beneficial in MelanomaMany Women Have Questions, Concerns About TamoxifenMelanoma Diagnoses Can Vary Widely Among PathologistsMany Women Mistaken on 'Side Effects' of Breast Cancer DrugMelanoma Biopsy Results Can Differ, Worrying PatientsNew Microscope Scans Breast Tumors During SurgeryCan You Recognize the Signs of Skin Cancer?Reduced Cancer-Independent Life Expectancy in Head, Neck CancerMore Breast Cancers Diagnosed at Late Stage With Medicaid CutsSimilar Skin Cancer Incidence Seen With TeledermatologyMedicaid Cuts Tied to Delayed Breast Cancer DiagnosesACOG: Shared Decision-Making Key to Breast Cancer ScreeningDrug, Herb Interactions Frequent for Cancer PatientsMany With Advanced Cancer Want Secondary Germline Findings InfoSecondhand Smoke Still Plagues Some Cancer SurvivorsBig Gap in Cancer Deaths Between Rich, Poor CountriesMany Doctors Silent on Cost of Cancer Care
LinksBook ReviewsSelf-Help Groups
Related Topics

Medical Disorders
Pain Management

Chemo Drug May Buy Time for Those With Bile Duct Cancer


HealthDay News
Updated: May 18th 2017

new article illustration

THURSDAY, May 18, 2017 (HealthDay News) -- The chemotherapy drug Xeloda may prolong survival in those struck by a type of digestive system cancer, a new study finds.

People with bile duct cancer who received the medication lived for an average of about 17 months longer than those who didn't take it, the researchers found. Based on the findings, the study authors suggested that Xeloda should be given routinely to patients with this disease.

Bile duct cancer -- which occurs in an area that connects the liver, gallbladder and the small intestine -- is rare and aggressive. It affects an estimated 8,000 people in the United States each year, according to the American Cancer Society.

A statement from Cancer Research UK, which funded the new study, said it's difficult to study treatments for bile duct cancer because so few patients are available to take part in clinical trials.

For the study, researchers gave capecitabine (Xeloda) to about half of 450 bile duct cancer patients who underwent surgery. The other half underwent surgery but didn't get the drug.

The average survival after surgery for those who took the drug was 53 months compared to 36 months for those who only had surgery, the findings showed.

"While rare, bile duct cancer is difficult to treat and until recently there has been very little progress in treating the disease," said lead researcher John Primrose, of the University of Southampton in the United Kingdom.

"Our results clearly show that patients who have surgery should be given capecitabine, as a result of which more will survive and with few side effects," he said in a Cancer Research UK news release.

The findings are to be presented at the American Society of Clinical Oncology's annual meeting in Chicago in June. Research presented at medical meetings is considered preliminary until published in a peer-reviewed journal.

More information

For more about bile duct cancer, visit the American Cancer Society.